Results 251 to 260 of about 97,473 (302)
Some of the next articles are maybe not open access.
Electrophysiology of phosphodiesterase inhibitors
The American Journal of Cardiology, 1989Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
G V, Naccarelli, R A, Goldstein
openaire +2 more sources
Phosphodiesterase inhibitors in psychiatric disorders
Psychopharmacology, 2023Challenges in drug development for psychiatric disorders have left much room for the introduction of novel treatments with better therapeutic efficacies and indices. As a result, intense research has focused on identifying new targets for developing such pharmacotherapies.
Mohammad Amin, Sadeghi +5 more
openaire +2 more sources
Xanthines and Phosphodiesterase Inhibitors
2016Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
D, Spina, C P, Page
openaire +2 more sources
[Phosphodiesterase inhibitors].
Annales de cardiologie et d'angeiologie, 1991Phosphodiesterase III inhibitors constitute a new therapeutic group for congestive cardiac failure. They inhibit the degradation of cyclic adenosine monophosphate and increase the intracellular calcium. They have a double inotropic and vasodilator haemodynamics occurs without any increase in the myocardial effect.
A, Sarkis, M, Pornin
openaire +1 more source
Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design, 2009PDE-5 inhibitors were originally studied in cardiovascular indications but were later developed and approved for on-demand treatment of erectile dysfunction (ED). A few years ago sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in once-daily ...
Giannitsas, Konstantinos +1 more
openaire +2 more sources
Phosphodiesterase inhibitors and lung diseases
2023Phosphodiesterase enzymes (PDE) have long been known as regulators of cAMP and cGMP, second messengers involved in various signaling pathways and expressed in a variety of cell types implicated in respiratory diseases such as airway smooth muscle and inflammatory cells making them a key target for the treatment of lung diseases as chronic obstructive ...
Ivana, Stolfa, Clive, Page
openaire +2 more sources
Phosphodiesterase inhibitors and the eye
Clinical & Experimental Ophthalmology, 2009AbstractPhosphodiesterase type 5 (PDE5) inhibitors are effective oral treatments for erectile dysfunction and have become one of the most widely prescribed medications worldwide. The mechanism of action is to reduce the degradation of cyclic GMP (cGMP) potentiating the effect of nitric oxide in the corpus cavernosum and allowing erectile function to ...
Nathan M, Kerr, Helen V, Danesh-Meyer
openaire +2 more sources
Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction
2017The nonspecific PDE inhibitors, particularly the methylxanthines: caffeine, pentoxifylline (PTX), and theophylline, are known to stimulate sperm motility in vitro and have been used to treat sperm prior to insemination. The in vivo effects are less dramatic.
Erma Z, Drobnis, Ajay K, Nangia
openaire +2 more sources
Disaggregatory action of phosphodiesterase inhibitors
Pharmacological Research Communications, 1981Summary Papaverine and three hypotensive xanthines were shown to disaggregate platelet clumps in anaesthetized cats. The order of disaggregatory potency was: IMBX > papaverine > > aminophylline ≫ xantinol nicotinate. This effect was not associated with the release of prostacyclin. It is concluded that disaggregatory action of papaverine and xanthines
M, Radomski, J, Swies, R J, Gryglewski
openaire +2 more sources
The new inotropic phosphodiesterase inhibitors
Archives Internationales de Physiologie et de Biochimie, 1984Compounds with phosphodiesterase inhibitory activity stimulate myocardial contractility by increasing the intracellular cyclic AMP concentrations. They can also increase Ca2+ entry and inhibit Ca2+ sequestration by the sarcoplasmic reticulum. Xanthines produce bronchodilation with associated venous and arteriolar dilation. However, their use is limited
D, el Allaf, V, D'Orio, J, Carlier
openaire +2 more sources